RIPK3 and diabetic kidney disease: GSK’872 is a specific inhibitor of RIPK3 activity that can suppress disease progression attributed to RIPK3 activation across multiple disease models.[19, 20] In this study, GSK’872 alleviated podocyte damage, reduced proteinuria, and delayed progression of DKD in STZ/HFD/UNI and db/db mice.